PDCD1 and non-small cell lung carcinoma: Nivolumab, an anti-PD-1 mAb that was also approved for use by the US FDA in 2014 as well, was assessed as a treatment for recurrent or metastatic squamous-cell carcinoma of the head and neck [20], advanced renal-cell carcinoma [38], and nonsquamous NSCLC [39].